Healio
SearchLoading
Healio
SearchLoading

American Academy of Ophthalmology Meeting
ByRamiro Ribeiro, MD, PhD
ByEamon N. Dreisbach
ByAnthony DeFino
Fact checked byChristine Klimanskis, ELS

Read more

December 20, 2024
1 min watch
Save

VIDEO: Duravyu for wet AMD shows positive 12-month outcomes vs. aflibercept

ByRamiro Ribeiro, MD, PhD
ByEamon N. Dreisbach
ByAnthony DeFino
Fact checked byChristine Klimanskis, ELS

CHICAGO — In this Healio Video Perspective from the AAO meeting, Ramiro Ribeiro, MD, PhD, of EyePoint Pharmaceuticals, shares phase 2 data investigating Duravyu for wet age-related macular degeneration treatment vs. aflibercept.

According to Ribeiro, Duravyu (vorolanib intravitreal insert) demonstrated comparable vision outcomes to aflibercept, as well as stabilization of central subfield thickness.

Additionally, 50% of patients treated with Duravyu did not require any supplemental anti-VEGF injections at 12 months, he said.

Sources/Disclosures

Collapse
Source:

Healio Interviews

Disclosures: Ribeiro reports being the chief medical officer for EyePoint Pharmaceuticals.

Read more from American Academy of Ophthalmology Meeting

View all

Read more about

wet age-related macular degeneration
aflibercept
retina
 

Related Content